调强放射治疗联合周剂量紫杉醇治疗食管癌的毒副反应观察  

Toxic Reactions after Late Course Intensity Modulated Radiation Therapy (IMRT) plus Concurrent Chemotherapy for Esophageal Carcinoma

作　　者：于忠华[1] 谢朝辉 张振才 刘金凤 王薇 刘晶 刘秀春 刘艳杰 

机构地区：[1]承德市中心医院,河北承德067000 [2]承德市肿瘤医院,河北承德067000

出　　处：《中国医药指南》2012年第4期11-12,共2页Guide of China Medicine

基　　金：承德市科学技术研究与发展计划项目(课题编号:201121067)

摘　　要：目的观察化疗同步调强放疗食管癌耐受性和毒性反应。方法放疗:调强技术,总量66Gy;化疗:紫杉醇全身用药方案,60mg静脉给药,放疗开始第一天给药1次,以此类推,每周用药一次,共6次。结果毒性反应主要是白细胞减少,Ⅲ级以上分别为21.6%,晚期放射反应主要为放射性食管炎。结论与单纯调强放射治疗相比,调强放射治疗同步化疗有提高食管癌生存率的趋势,但并不增加晚期放射反应。Objeetive To evaluate the efficacy of combined chemotherapy with weeky paclitaxel plus concurrent cocal intensity modulated radiation therapy （IMRT） in treatment of esophageal carcinoma. Methods All patients were given with 6Mvx-ray, The total close varied up to 66Gy. Paclitaxel 60mg was given through in stravenous dripping for weeky administrated once per week before radiotherapy for 6weeks with premedication of lhour intravenous infusion. Results No significant differences between the main common late adverse reactions in the two groups were found, including esophageal stricture and lung fibrosis. The major toxic reactions were leucopenia. Grade III-IV leucopenia was 21.6%. Conclusions In comparison with HF, the combined treatment tends to promote the survival rate, yet does not increase the late adverse reactions.

关 键 词：食管癌 调强放疗 紫杉醇 毒性反应 

分 类 号：R735.1[医药卫生—肿瘤]